Josefina Durán1, Margarita Bockorny2, Deepan Dalal3, Michael LaValley2, David T Felson4. 1. Rheumatology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA. 3. Division of Rheumatology, Department of Medicine, Brown University Warren Alpert School of Medicine, Providence, Rhode Island, USA. 4. Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA Arthritis Research UK Epidemiology Unit, Manchester NIHR Biomedical Research Unit, University of Manchester, Manchester, UK.
Abstract
OBJECTIVES: To evaluate if optimal dose of either oral or injectable regimens of methotrexate (MTX) of 25 mg/week was used in the comparator arms of studies comparing biologic drugs with MTX in rheumatoid arthritis (RA). METHODS: A systematic literature search was carried out in MEDLINE, EMBASE and the Cochrane Library databases for randomised controlled trials comparing biologics with MTX in RA. A systematic review was performed among studies that met predefined criteria focusing on assessment of dose of MTX used in the comparator arm. Study authors were contacted when necessary. Study quality was assessed. RESULTS: A total of 3276 references were identified and 13 trials were included. We obtained maximal dose and regimen for all. The maximal dose of MTX used in the comparator arm of the trials was no more than 20 mg/week in any trial and for all but one trial, MTX was given orally and not by injection. The trial that used an injectable form reached a maximum of 15 mg/week. CONCLUSIONS: A suboptimal dose of MTX was used in biological clinical trials performed in RA, particularly regarding route of administration. This may have biased findings in favour of biological agents. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: To evaluate if optimal dose of either oral or injectable regimens of methotrexate (MTX) of 25 mg/week was used in the comparator arms of studies comparing biologic drugs with MTX in rheumatoid arthritis (RA). METHODS: A systematic literature search was carried out in MEDLINE, EMBASE and the Cochrane Library databases for randomised controlled trials comparing biologics with MTX in RA. A systematic review was performed among studies that met predefined criteria focusing on assessment of dose of MTX used in the comparator arm. Study authors were contacted when necessary. Study quality was assessed. RESULTS: A total of 3276 references were identified and 13 trials were included. We obtained maximal dose and regimen for all. The maximal dose of MTX used in the comparator arm of the trials was no more than 20 mg/week in any trial and for all but one trial, MTX was given orally and not by injection. The trial that used an injectable form reached a maximum of 15 mg/week. CONCLUSIONS: A suboptimal dose of MTX was used in biological clinical trials performed in RA, particularly regarding route of administration. This may have biased findings in favour of biological agents. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: Jacqueline Detert; Hans Bastian; Joachim Listing; Anja Weiß; Siegfried Wassenberg; Anke Liebhaber; Karin Rockwitz; Rieke Alten; Klaus Krüger; Rolf Rau; Christina Simon; Eva Gremmelsbacher; Tanja Braun; Bettina Marsmann; Vera Höhne-Zimmer; Karl Egerer; Frank Buttgereit; Gerd-R Burmester Journal: Ann Rheum Dis Date: 2012-06-27 Impact factor: 19.103
Authors: P P Tak; W F Rigby; A Rubbert-Roth; C G Peterfy; R F van Vollenhoven; W Stohl; E Hessey; A Chen; H Tyrrell; T M Shaw Journal: Ann Rheum Dis Date: 2010-10-11 Impact factor: 19.103
Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green Journal: Arthritis Rheum Date: 2006-01
Authors: Paul Emery; Roy M Fleischmann; Larry W Moreland; Elizabeth C Hsia; Ingrid Strusberg; Patrick Durez; Peter Nash; Eric Jason B Amante; Melvin Churchill; Won Park; Bernardo Antonio Pons-Estel; Mittie K Doyle; Sudha Visvanathan; Weichun Xu; Mahboob U Rahman Journal: Arthritis Rheum Date: 2009-08
Authors: Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich Journal: Lancet Date: 2008-07-16 Impact factor: 79.321
Authors: Gerd R Burmester; William F Rigby; Ronald F van Vollenhoven; Jonathan Kay; Andrea Rubbert-Roth; Ariella Kelman; Sophie Dimonaco; Nina Mitchell Journal: Ann Rheum Dis Date: 2015-10-28 Impact factor: 19.103
Authors: R Westhovens; M Robles; A C Ximenes; S Nayiager; J Wollenhaupt; P Durez; J Gomez-Reino; W Grassi; B Haraoui; W Shergy; S-H Park; H Genant; C Peterfy; J-C Becker; A Covucci; R Helfrick; J Bathon Journal: Ann Rheum Dis Date: 2009-01-05 Impact factor: 19.103
Authors: Mohammad A Y Alqudah; Sayer Al-Azzam; Karem Alzoubi; Mohammad Alkhatatbeh; Khaldoon Alawneh; Ola Alazzeh; Bayan Ababneh Journal: Inflammopharmacology Date: 2017-02-08 Impact factor: 4.473
Authors: Sharzad Emamikia; Elizabeth V Arkema; Noémi Györi; Jacqueline Detert; Katerina Chatzidionysiou; Maxime Dougados; Gerd Rüdiger Burmester; Ronald van Vollenhoven Journal: RMD Open Date: 2016-09-06
Authors: Andreea M Bujor; Sahar Janjua; Michael P LaValley; Josefina Duran; Jürgen Braun; David T Felson Journal: PLoS One Date: 2019-09-06 Impact factor: 3.240